7.340USD-1.34%Mkt Cap: 755.76M USDP/E: —Last update: 2026-06-01
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like par…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap755.76M USD
Enterprise Value674.56M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-106.19M USD
Revenue/Share—
Last Price7.340 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees113
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.68
PEG—
EV/EBITDA-5.74
EV/Revenue—
P/S—
P/B4.47
EPS (TTM)-1.71
EPS (Forward)-2.03
52W Range
4.73054% of range9.535
52W High9.535 USD
52W Low4.730 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-77.56%
ROA-62.68%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-84.74M USD
CapEx (TTM)447.00K USD
FCF Margin—
FCF Yield-6.82%
Net Debt-97.74M USD
Net Debt/EBITDA0.83
Balance Sheet
Debt/Equity0.13
Current Ratio7.09
Quick Ratio6.87
Book Value/Sh1.672 USD
Cash/Share1.110 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)18.80 USD
Target Range15.00 USD – 24.00 USD
# Analysts5
Ownership
Shares Out.103.39M
Float93.38M
Insiders1.01%
Institutions51.03%
Short Interest
Short Ratio4.5d
Short % Float3.66%
Short % Out.3.05%
Shares Short3.16M
Short (prev mo.)2.01M
Technical
SMA 507.211 (+1.8%)
SMA 2006.250 (+17.4%)
Beta0.37
S&P 52W Chg27.94%
Avg Vol (30d)640.11K
Avg Vol (10d)494.00K
Technical Indicators
RSI (14)47.7
MACD0.0740
MACD Signal0.1554
MACD Hist.-0.0814
BB Upper8.738 USD
BB Middle7.845 USD
BB Lower6.953 USD
BB Width22.75%
ATR (14)0.3998 USD
Vol Ratio (20d)0.23x